1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow Noonan syndrome 3: new trials by email Literature Review of Noonan syndrome 3 trials Research Report on Noonan syndrome 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - BRAF NP_004324.2:p.V600X, KRAS wt Allele | Phase 1 | Completed | M.D. Anderson Cancer Center | 47 | 2013-02-15 | 2026-04-23 |
Colorectal Neoplasms (1) · Neoplasm Metastasis (1)
Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Rectal Diseases (1)
Cetuximab (1) · Irinotecan (1) · Vemurafenib (1)
M.D. Anderson Cancer Center (1)
United States (1)
David S Hong (1)
P30CA016672 (1), R01CA187238 (1)